<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220601055047N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-03</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>The effect ofTranscutaneous electrical nerve stimulation onrestless legs syndrome</public_title>
      <acronym></acronym>
      <scientific_title>The effect ofTranscutaneous electrical nerve stimulation on the severity of restless legs syndrome in hemodialysis patients referred to the dialysis ward of Sabzevar Vasei Hospital and Imam Khomeini Hospital in Esfarayen</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/63925</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sequence of random allocation and the list of blocks, by the statistical consultant and to
Software help will be available. website
https://www.sealedenvelope.com is a useful site for production
The random sequence for randomization is block type. This site
It is designed in such a way that there is a limit in the number of groups
There is no random assignment. From block method to volume 4 to create
A random allocation sequence is used. According to the total number of samples
The requirement for the study is 60 patients. 30 patients in the intervention group
A and 30 patients are in group B. There are 15 quadruple blocks including two
Group A and B are randomly designed through the software, for example
Continue on...... (ABAB), (BBAB), (AABB), (ABBA), (BAAB)
Based on the sample size, 60 envelopes 30 envelopes including paper containing A and 30).
An envelope containing B is prepared.Based on the list of blocks
A randomly prepared quadruple, a trained person outside the research team,
He is responsible for randomly assigning patients, after the arrival of each
Patient and hospitalized in the special ward, according to 15 blocks of four prepared in
The first stage of each patient randomly in intervention group A and group B
The samples will be placed and the sample process will be done sequentially
Sampling will be done, the code of each patient to his family member as well
Will allocate data. People in the order of their entry into the study and form
Randomly assigned to the desired group through randomized blocks
Finds. For example, according to the ABAB block, each patient after entering the
study, entered into the intervention, sham, intervention and sham groups, respectively
will be This process continues until the last block is selected, Blinding description: In this study, patients in each intervention and control group (sham) will be considered as a separate room for not exchanging information with patients referred for interview and training, and patients will be reminded not to exchange information with other patients during the study.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Severity of restless leg syndrome in hemodialysis patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this study, after confirming restless leg syndrome, TENS electric current with a frequency of 100 Hz will be performed for the patients of the test group for 3 times and for 20 minutes in each stage. Intervention 2: Control group: In this study, after confirming restless legs syndrome, TENS electric current with a frequency of 20 Hz will be performed for the patients of the test group for 3 times and for 20 minutes in each stage.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data, such as the information related to the main outcome or the like, will be shared.

When:
The access period begins 4 months after the results are published.

To whom:
Researchers working in academic institutions and hospitals

Conditions:
1- For the use of other patients who have this restless legs syndrome, except hemodialysis patients
2- To provide new research work with more patients and new variables

Where to obtain:
Sabzevar Faculty of Medical Sciences - University Central Library
 Contact number: 05144018300
Esfrain Faculty of Medical Sciences - Imam Khomeini Hospital (RA) - Abolfazl Kalmishi09232709619 : contact number

How to obtain:
Go to the library of Sabzevar University of Medical Sciences and refer to the librarian and receive the electronic pdf of the thesis
Also, contact the author of the thesis and send the thesis to the target person

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Abolfazal Kalmishi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Esfrain, Nawab St., Shahid Moradi Alley</address>
        <city>Esfrain</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9661665596</zip>
        <telephone>+98 58 3722 6852</telephone>
        <email>a.kalmish2020@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Abolfazal kalmishi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Esfrain, Nawab St., Shahid Moradi Alley</address>
        <city>Esfrain</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9661665596</zip>
        <telephone>+98 58 3722 6852</telephone>
        <email>a.kalmish2020@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Hemodialysis patients aged 18-75 years and older
suffering from restless leg syndrome based on the self-report of the hemodialysis patient
no history of neurological and mental illness except restless leg syndrome
Absence of vascular diseases except restless leg syndrome
absence of neuromuscular disorders, absence of crisis
experience during the last 3 months</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient's unwillingness to cooperate
Antispasmodic use in the past two weeks
Anticonvulsant use within the past two weeks
Use of sedatives in the past two weeks
Use of antidepressants in the past two weeks
Use of herbal medicines during the last two weeks</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>N18.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Chronic kidney disease, stage 5</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this study, after confirming restless leg syndrome, TENS electric current with a frequency of 100 Hz will be performed for the patients of the test group for 3 times and for 20 minutes in each stage.</i_keyword>
      <i_keyword>Control group: In this study, after confirming restless legs syndrome, TENS electric current with a frequency of 20 Hz will be performed for the patients of the test group for 3 times and for 20 minutes in each stage.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of restless legs syndrome. Timepoint: 3 shifts of 20 minutes. Method of measurement: Restless Leg Syndrome International Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-13</approval_date>
        <contact_name>Research Ethics Committee of Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Sabzevar, Tawheed Shahr Blvd., above the Martyrs' Tomb, University Campus Building, Educational Assistant Sabzevar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
